Talimogene Laherparepvec
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Talimogene Laherparepvec
- Talimogene Laherparepvec: From Melanoma to CMM7 (Hereditary Cutaneous Melanoma)
Talimogene Laherparepvec: From Melanoma to CMM7 (Hereditary Cutaneous Melanoma)
One-Sentence Summary
Talimogene laherparepvec (T-VEC) is an oncolytic herpes simplex virus type 1 (HSV-1)-based immunotherapy administered by direct intralesional injection, publicly known to be approved for unresectable cutaneous, subcutaneous, and nodal melanoma lesions. The TxGNN model predicts it may also be effective for CMM7 (a hereditary/familial cutaneous melanoma susceptibility phenotype), but this prediction is currently supported by no registered clinical trials and no literature — it is a pure AI-score-driven hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this Evidence Pack’s EU licensing data (drug is not marketed in the EU per this dataset). Publicly known original indication: melanoma (unresectable cutaneous/subcutaneous/nodal lesions). |
| Predicted New Indication | CMM7 (Cutaneous Malignant Melanoma, susceptibility locus 7 — hereditary/familial melanoma) |
| TxGNN Prediction Score | 99.20% |
| Evidence Level | L5 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack (marked as a data gap). Based on publicly known information, talimogene laherparepvec is a genetically modified, replication-competent oncolytic HSV-1 vector engineered to selectively replicate in tumor cells, lyse them, and release GM-CSF to stimulate local and systemic antitumor immune responses; it is delivered exclusively by direct intralesional injection.
CMM7 is not a distinct tumor type but a designation used in melanoma genetics for a hereditary/familial susceptibility locus associated with cutaneous malignant melanoma. In that sense, the predicted “new indication” sits within the same disease family as T-VEC’s established use — patients with CMM7-associated hereditary melanoma would still present with cutaneous melanoma lesions that are, in principle, anatomically and biologically similar to those already treated with T-VEC.
Because CMM7 reflects a genetic predisposition rather than a separate tumor biology, the mechanistic rationale is plausible by extension of the existing melanoma indication. However, this Evidence Pack does not currently contain any studies specifically enrolling or reporting on CMM7-associated melanoma patients, so this remains an unverified, score-only hypothesis rather than a mechanistically or clinically substantiated prediction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
No EU marketing authorization records are available for this drug in the current dataset (EU market status: Not Marketed; 0 authorizations on file).
Cytotoxicity (Antineoplastic Drugs Only)
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy (oncolytic viral immunotherapy — not a conventional cytotoxic agent) |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Please refer to the SmPC warnings and precautions |
| Handling Protection | Please refer to the SmPC warnings and precautions (biohazard/live viral vector handling precautions typically apply) |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite ranking highest by TxGNN score (99.20%) and having plausible conceptual proximity to the drug’s known melanoma indication, CMM7 currently has zero registered clinical trials and zero literature support (L5, model prediction only). Critical safety data (warnings, contraindications) and MOA data are flagged as blocking/high-severity data gaps in this Evidence Pack, preventing any safety pre-assessment.
To proceed, the following is needed:
- Resolve the blocking data gap: TFDA/EMA SmPC warnings and contraindications for talimogene laherparepvec
- Resolve the high-severity data gap: formal mechanism of action (MOA) documentation via DrugBank
- Conduct a targeted search of clinical trial registries and literature specifically for T-VEC use in hereditary/familial melanoma (CMM7) populations
- Note: among the other 9 predicted indications in this pack, non-small cell squamous lung carcinoma (rank 8, L2) already has a completed Phase 1b/2 basket trial (NCT02509507, n=127) and may warrant separate evaluation as a more evidence-backed candidate than CMM7.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.